

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-4 (Withdrawn)

Claim 5 (Cancelled)

Claim 6 (Withdrawn)

Claim 7 (Cancelled)

Claim 8 (Withdrawn)

Claim 9 (Presently Amended) A vaccine composition comprising a non-human 5T4 antigen as the an immunizing agent, and a pharmaceutically acceptable carrier.

Claim 10 (Presently Amended) A The vaccine composition according to claim 9, further comprising one or more adjuvants.

Claim 11 (Presently Amended) A The vaccine composition according to claim 9, wherein the 5T4 antigen is a modified 5T4 antigen and wherein said antigen is comprising a peptide epitope of 5T4 antigen, and wherein said modified 5T4 antigen induces a CTL response.

Claim 12 (Presently Amended) A method for eliciting an immune anti-tumor immunotherapeutic response in a subject, comprising immunizing the subject with a 5T4 antigen, wherein the 5T4 antigen induces an anti-tumor immunotherapeutic response to a tumor in the subject.

Claim 13 (Withdrawn)

Claim 14 (Presently Amended) A The method according to claim 12, wherein the 5T4 antigen is a modified 5T4 antigen comprising an HLA CTL

peptide epitope of 5T4 antigen, and wherein said antigen induces anti-tumor immunotherapeutic response comprises a CTL response.

Claim 15 (Withdrawn)

Claim 16 (Presently Amended) A The method according to claim 12, wherein the immune anti-tumor immunotherapeutic response is a CTL response or comprises an antibody response.

Claim 17 (Cancelled)

Claims 18-34 (Withdrawn)

Claims 35-40 (Cancelled)

Claims 41-45 (Withdrawn)

Claim 46 (New) An anti-tumor immunotherapeutic vaccine composition, comprising a modified 5T4 antigen and a pharmaceutically acceptable carrier, wherein said modified 5T4 antigen comprises an HLA CTL peptide epitope of unmodified 5T4 antigen.

Claim 47 (New) The vaccine composition according to claim 46, wherein said modified 5T4 antigen is a human modified 5T4 antigen.

Claim 48 (New) The vaccine composition according to claim 9, wherein said non-human 5T4 antigen is a murine antigen.

Claim 49 (New) The vaccine composition according to claim 9, wherein said non-human 5T4 antigen is a canine antigen.

Claim 50 (New) The vaccine composition according to claim 46, wherein said modified 5T4 antigen comprises a peptide sequence selected from the group consisting of:

(a)     FLTGNQLAV (SEQ ID NO:5);

must  
be  
unmodified otherwise  
isolate V.commt

- (b) ALIGAIFLL (SEQ ID NO:6);
- (c) SLQTSYVFL (SEQ ID NO:7);
- (d) AIFLLVLYL (SEQ ID NO:8);
- (e) GLPHIRVFL (SEQ ID NO:9);
- (f) FLGIVLALI (SEQ ID NO:10);
- (g) NLTEVPPTDL (SEQ ID NO:11);
- (h) NLFLTGNQL (SEQ ID NO:12);
- (i) FLYLP RDVL (SEQ ID NO:13);
- (j) VLYLNRKG I (SEQ ID NO:14);
- (k) LIGAIFLLV (SEQ ID NO:15);
- (l) FLDNNPWVC (SEQ ID NO:16); and
- (m) HMADMVTWL (SEQ ID NO:17).

Claim 51 (New) The vaccine composition according to claim 46, wherein said modified 5T4 antigen comprises a peptide sequence selected from the group consisting of:

- (a) YMADMVAWL (SEQ ID NO:18);
- (b) NLLEVPADL (SEQ ID NO:19);
- (c) FLTGNQMTV (SEQ ID NO:20);
- (d) ALIGAIFLL (SEQ ID NO:21);
- (e) FLFLPRDLL (SEQ ID NO:22);
- (f) SLQTSYVFL (SEQ ID NO:23);
- (g) AIFLLVLYL (SEQ ID NO:24);
- (h) GLAHVKVFL (SEQ ID NO:25);
- (i) FLGIVLALI (SEQ ID NO:26); and
- (j) VLYLNRKG (SEQ ID NO:27).

Claim 52 (New) The method according to claim 12, wherein the 5T4 antigen is a modified 5T4 antigen.